



**FemmePharma**  
GLOBAL HEALTHCARE, INC.

## **FemmePharma Invited to Present at Venture Fair for East Coast's Leading Biotechnology Companies**

Pharmaceutical Company Chosen Through Competitive Process to Speak at BIO VentureForum East in Philadelphia, Nov. 17-19

**October 6, WAYNE, PA - FemmePharma, Inc.**, a late stage prescription pharmaceutical company focused solely on the diseases and disorders disproportionately affecting women, has been chosen to be a Presenting Company at this year's BIO VentureForum East 2003 to be held at the Philadelphia Convention Center Nov. 17-19.

"BIO VentureForum East 2003 is the premier venture fair on the East Coast for life science, biotechnology and healthcare companies. Due to the competitiveness of the application process, we are grateful for and excited about the opportunity to share FemmePharma's achievements and objectives with this audience," said Gerianne Tringali DiPiano, the company's President & CEO.

FemmePharma is seeking up to \$10 million in investment capital in order to complete development of its urinary incontinence product and its fibrocystic breast disease product. Working capital is also being sought so FemmePharma can expand its commercial operations. The Company will open a Phase IIa human clinical trial for its urinary incontinence drug in early 2004. This is FemmePharma's second product to enter human clinical trials. Its first product, a drug for endometriosis, is preparing to enter Phase III.

BIO VentureForum East 2003 is sponsored by the Biotechnology Industry Organization (BIO). The venture fair features the most promising seed, early and late stage biotechnology and healthcare companies. An international audience of the most prestigious life science venture capital firms will be in attendance. This year, BIO is collaborating with the Greater Philadelphia Venture Group to produce the BIO VentureForum East 2003 concurrently with the Mid-Atlantic Venture Fair, a premier East Coast event for entrepreneurs and financiers.

### **About FemmePharma, Inc.**

FemmePharma was founded by Gerianne Tringali-DiPiano in 1996 to target needs within the estimated \$35 billion women's healthcare pharmaceutical market. The company is preparing for its Phase III trial for its first drug, a new treatment for endometriosis, and its Phase II trial for its drug to treat female urinary incontinence. FemmePharma is devoted to developing safe and effective drugs that minimize or eliminate unpleasant side effects associated with many medications by designing them in a manner that is specifically suited to a woman's physiology, with an eye toward the changing needs of women throughout their lives. The company has a number of drugs in development based on its proprietary

■ 37 West Avenue • Second Floor  
■ Wayne, Pennsylvania 19087  
■ Tel: 610.995.0801  
■ Fax: 610.995.0825

technologies, including new therapeutic options for fibrocystic breast disease and the prevention of HIV/STD transmission. For more information about FemmePharma, please visit its website at [www.fpghc.com](http://www.fpghc.com).

###